# A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114

> **NCT05200273** · PHASE1 · UNKNOWN · sponsor: **Akeso** · enrollment: 30 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors
- Malignancy
- Metastasis

## Interventions

- **DRUG:** AK114

## Key facts

- **NCT ID:** NCT05200273
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-15
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05200273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05200273, "A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05200273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*